DexCom, Inc. (NASDAQ:DXCM) Q2 2024 Earnings Conference Call July 25, 2024 4:30 PM ET
Corporate Participants
Sean Christensen - Vice President of Finance, and Investor Relations
Kevin Sayer - Chairman, President, and Chief Executive Officer
Jereme Sylvain - Chief Financial Officer
Conference Call Participants
Robbie Marcus - JPMorgan
Larry Biegelsen - Wells Fargo
Jeff Johnson - Baird
Magaret Andrew - William Blair
Travis Steed - Bank of America
Matt Taylor - Jefferies
Danielle Antalffy - UBS
Joanne Wuensch - Citibank
Matthew O'Brien - Piper Sandler
Sam Eiber - BTIG
Mathew Blackman - Stifel
Jason Bedford - Raymond James
Steve Lichtman - Oppenheimer
Mike Polark - Wolfe Research
Shagun Singh - RBC Capital Markets
Bill Plovanic - Canaccord Genuity
Chris Pasquale - Nephron
Matt Miksic - Barclays
Operator
Welcome to the Dexcom Second Quarter 2024 Earnings Release Conference Call. My name is Abby and I'll be your operator for today's call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session. [Operator Instructions] As a reminder, the conference is being recorded.
I will now turn the call over to Sean Christensen. You may begin.
Sean Christensen
Thank you, Abby, and welcome to Dexcom's second quarter 2024 earnings call. Our agenda begins with Kevin Sayer, Dexcom's Chairman, President, and CEO, who will summarize our recent highlights and ongoing strategic initiatives, followed by a financial review and outlook from Jereme Sylvain, our Chief Financial Officer. Following our prepared remarks, we will open the call up for your questions.
At that time, we ask analysts to limit themselves to one question each so we can provide an opportunity for everyone participating today. Please note that there are also slides available related to our second Quarter 2024 performance on the Dexcom Investor Relations website on the Events and Presentations page. With that, let's review our Safe Harbor Statement.
Some of the statements we will make on today's call may constitute forward-looking statements. These statements reflect management's intentions, beliefs, and expectations about future events, strategies, competition, products, operating plans, and performance. All forward-looking statements included on this call are made as of the date hereof based on information currently available to Dexcom, are subject to various risks and uncertainties, and actual results could differ materially from those anticipated in the forward-looking statements.
The factors that could cause actual results to differ materially from those expressed or implied by any of these forward-looking statements are detailed in Dexcom's Annual Report on Form 10-K, most recent quarterly report on Form 10-Q, and other filings of the Securities and Exchange Commission. Except as required by law, we assume no obligation to update any such forward-looking statements after the date of this call or to conform these forward-looking statements to actual results. Additionally, during the call, we will discuss certain financial measures that have not been prepared in accordance with GAAP.